La Jolla Pharmaceutical Company Company Profile (NASDAQ:LJPC)

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company logoLa Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. Its product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. The Company is developing LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH). The Company is developing LJPC-401 for the treatment of iron overload, which occurs as a result of diseases, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. It is developing LJPC-30Sa and LJPC-30Sb not only for the treatment of serious bacterial infections but also for the potential treatment of rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: LJPC
  • CUSIP:
Key Metrics:
  • Previous Close: $16.97
  • 50 Day Moving Average: $19.74
  • 200 Day Moving Average: $19.60
  • 52-Week Range: $14.24 - $28.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.80
  • P/E Growth: -0.34
  • Market Cap: $309.77M
  • Outstanding Shares: 18,254,000
  • Beta: 0.58
Profitability:
  • Net Margins: -6,921.47%
  • Return on Equity: -66.51%
  • Return on Assets: -59.13%
Debt:
  • Current Ratio: 12.00%
  • Quick Ratio: 12.00%
Additional Links:
Companies Related to La Jolla Pharmaceutical Company:

Analyst Ratings

Consensus Ratings for La Jolla Pharmaceutical Company (NASDAQ:LJPC) (?)
Ratings Breakdown: 4 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.20)
Consensus Price Target: $39.40 (132.17% upside)

Analysts' Ratings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Show:
DateFirmActionRatingPrice TargetDetails
1/24/2017Chardan CapitalReiterated RatingTop Pick$75.00View Rating Details
1/23/2017Jefferies Group LLCReiterated RatingBuy$27.00View Rating Details
9/8/2016Cowen and CompanySet Price TargetBuy$40.00View Rating Details
6/22/2016SunTrust Banks, Inc.Initiated CoverageBuy$30.00View Rating Details
5/24/2016Lake Street CapitalInitiated CoverageBuy$25.00View Rating Details
1/19/2016Noble FinancialReiterated RatingBuy$37.00View Rating Details
5/11/2015HC WainwrightLower Price TargetBuy$29.00 -> $20.00View Rating Details
4/20/2015Oppenheimer Holdings, Inc.Initiated CoverageOutperform$43.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017($1.20)N/AView Earnings Details
8/8/2016Q2($0.99)($0.90)ViewN/AView Earnings Details
5/6/2016Q416($0.74)($0.96)ViewN/AView Earnings Details
11/6/2015Q315($0.71)($0.70)ViewN/AView Earnings Details
8/7/2015Q215($0.61)($0.70)ViewN/AView Earnings Details
3/16/2015Q414($0.37)($0.45)ViewN/AView Earnings Details
11/12/2014Q314($0.31)($0.37)ViewN/AView Earnings Details
8/14/2014Q214($0.69)($0.63)ViewN/AView Earnings Details
5/2/2014($0.91)($0.93)ViewN/AView Earnings Details
3/31/2014($0.24)($0.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Current Year EPS Consensus Estimate: $-4.32 EPS
Next Year EPS Consensus Estimate: $-4.46 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.95)($0.95)($0.95)
Q3 20163($1.00)($0.97)($0.98)
Q4 20163($1.08)($0.77)($0.95)
Q1 20172($1.39)($1.19)($1.29)
Q2 20172($1.15)($0.98)($1.07)
Q3 20172($1.22)($0.99)($1.11)
Q4 20172($1.28)($1.20)($1.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Insider Ownership Percentage: 26.43%
Institutional Ownership Percentage: 88.16%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2016Kevin C TangDirectorBuy139,035$19.82$2,755,673.70View SEC Filing  
3/4/2016Kevin C TangDirectorBuy20,000$19.85$397,000.00View SEC Filing  
3/1/2016George F TidmarshCEOBuy2,000$16.57$33,140.00View SEC Filing  
9/28/2015Lakhmir S ChawlaInsiderBuy485$27.75$13,458.75View SEC Filing  
9/10/2015Kevin C TangDirectorBuy80,000$38.00$3,040,000.00View SEC Filing  
8/21/2015Kevin C TangDirectorBuy170,000$27.11$4,608,700.00View SEC Filing  
6/26/2015Kevin C TangDirectorBuy110,000$23.58$2,593,800.00View SEC Filing  
6/24/2015Kevin C TangDirectorBuy220,000$22.23$4,890,600.00View SEC Filing  
6/23/2015Kevin C TangDirectorBuy53,836$22.27$1,198,927.72View SEC Filing  
6/22/2015Kevin C TangDirectorBuy77,850$21.41$1,666,768.50View SEC Filing  
5/13/2015Kevin C TangDirectorBuy190,583$18.24$3,476,233.92View SEC Filing  
5/12/2015George F TidmarshCEOBuy4,000$18.37$73,480.00View SEC Filing  
12/15/2014Kevin C TangDirectorBuy232,343$12.84$2,983,284.12View SEC Filing  
12/11/2014George F TidmarshCEOBuy4,000$11.38$45,520.00View SEC Filing  
9/26/2014George F TidmarshCEOBuy2,000$9.35$18,700.00View SEC Filing  
9/26/2014Kevin C TangDirectorBuy169,555$9.14$1,549,732.70View SEC Filing  
9/25/2014Kevin C TangDirectorBuy30,500$9.17$279,685.00View SEC Filing  
9/24/2014Kevin C TangDirectorBuy95,000$9.10$864,500.00View SEC Filing  
9/18/2014George F TidmarshCEOBuy5,000$9.18$45,900.00View SEC Filing  
7/23/2014George F TidmarshCEOBuy19,000$10.50$199,500.00View SEC Filing  
5/21/2014George TidmarshCEOBuy12,000$7.37$88,440.00View SEC Filing  
4/14/2014George TidmarshCEOBuy8,000$9.53$76,240.00View SEC Filing  
2/7/2014George F TidmarshCEOBuy3,000$7.25$21,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for La Jolla Pharmaceutical Company (NASDAQ:LJPC)
DateHeadline
News IconShould You Sell La Jolla Pharmaceutical Company Based On Current Broker Views? - NewsDen (NASDAQ:LJPC)
newsden.net - February 22 at 6:28 PM
News IconConsensus Take: La Jolla Pharmaceutical Company (NASDAQ:LJPC) Earnings & Ratings Watch - Aiken Advocate (NASDAQ:LJPC)
aikenadvocate.com - February 20 at 10:18 AM
News IconIs there Upside to La Jolla Pharmaceutical Company (NASDAQ:LJPC) ? - Rockville Register (NASDAQ:LJPC)
rockvilleregister.com - February 17 at 4:28 PM
News IconAre Insiders Pocketing Their Own Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC)? - Winfield Review (NASDAQ:LJPC)
winfieldreview.com - February 14 at 12:23 AM
News IconStock in Review: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Benton Bulletin (NASDAQ:LJPC)
bentonbulletin.com - February 11 at 6:20 PM
News IconShares of La Jolla Pharmaceutical Company (LJPC) Sees Large Outflow of Money - Highland Mirror (NASDAQ:LJPC)
www.highlandmirror.com - February 1 at 12:10 AM
News IconInvestor Monitor: Narrowing in on La Jolla Pharmaceutical Company (NASDAQ:LJPC) - The Tribune (NASDAQ:LJPC)
lakecitytribune.com - January 28 at 3:58 AM
News IconEarnings in Full Force, Analysts Take Aim at La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Wall Street Beacon (NASDAQ:LJPC)
wsbeacon.com - January 26 at 8:05 PM
benzinga.com logoHere's What Makes La Jolla Pharma A 2017 Top Pick At Chardan (NASDAQ:LJPC)
www.benzinga.com - January 24 at 7:00 PM
News IconTang Capital Management LLC Upped La Jolla Pharmaceutical Co (LJPC) Position by $3.20 Million (NASDAQ:LJPC)
randolphguide.com - January 24 at 7:00 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of La Jolla Pharmaceutical Company (NASDAQ:LJPC)
finance.yahoo.com - January 23 at 6:37 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Wall Street Beacon (NASDAQ:LJPC)
wsbeacon.com - January 22 at 4:05 AM
4-traders.com logoLa Jolla Pharmaceutical : Sepsis Alliance Announces National Partnership with La Jolla Pharmaceutical (NASDAQ:LJPC)
www.4-traders.com - January 20 at 7:01 PM
streetinsider.com logoSepsis Alliance Announces National Partnership with La Jolla Pharmaceutical (NASDAQ:LJPC)
www.streetinsider.com - January 20 at 7:01 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Wall Street Beacon (NASDAQ:LJPC)
wsbeacon.com - January 17 at 11:40 PM
News IconTracking Corporate Insiders: What Are They Doing With La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Wall Street Beacon (NASDAQ:LJPC)
wsbeacon.com - January 17 at 11:40 PM
News IconStock Momentum Skidding to a Halt For La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Wall Street Beacon (NASDAQ:LJPC)
wsbeacon.com - January 17 at 11:40 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Prospect Journal (NASDAQ:LJPC)
prospectjournal.com - January 16 at 6:54 PM
News IconAnalysts Take: La Jolla Pharmaceutical Company (NASDAQ:LJPC) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:LJPC)
aikenadvocate.com - January 16 at 8:27 AM
News IconStock On Watch: What's Propelling La Jolla Pharmaceutical ... - Fair View Times (NASDAQ:LJPC)
fairviewtimes.com - January 12 at 6:47 PM
News IconWill The Needle Move For La Jolla Pharmaceutical Company (NASDAQ:LJPC) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:LJPC)
wsbeacon.com - January 12 at 6:47 PM
capitalcube.com logoLa Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : January 5, 2017 (NASDAQ:LJPC)
www.capitalcube.com - January 5 at 7:41 PM
biz.yahoo.com logoLA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan (NASDAQ:LJPC)
biz.yahoo.com - January 5 at 7:41 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Prospect Journal (NASDAQ:LJPC)
prospectjournal.com - January 2 at 6:13 PM
News IconNotable Wednesday Option Activity: SCSS, LJPC, PRU (NASDAQ:LJPC)
www.stockoptionschannel.com - December 28 at 6:13 PM
capitalcube.com logoLa Jolla Pharmaceutical Co. – Value Analysis (NASDAQ:LJPC) : December 27, 2016 (NASDAQ:LJPC)
www.capitalcube.com - December 27 at 6:15 PM
capitalcube.com logoLa Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : December 26, 2016 (NASDAQ:LJPC)
www.capitalcube.com - December 26 at 10:21 AM
capitalcube.com logoETFs with exposure to La Jolla Pharmaceutical Co. : December 21, 2016 (NASDAQ:LJPC)
www.capitalcube.com - December 21 at 7:08 PM
investornewswire.com logoSentiments And Ratings Alert: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Investor Newswire (NASDAQ:LJPC)
www.investornewswire.com - December 21 at 7:21 AM
News IconFollowing the Numbers for La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Liberty News (NASDAQ:LJPC)
libertynewsrecord.com - December 21 at 7:21 AM
News IconAre There Catalysts to Propel This Stock Forward: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Prospect Journal (NASDAQ:LJPC)
prospectjournal.com - December 20 at 11:59 AM
News IconStock Concentration on Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) - OIB News (NASDAQ:LJPC)
oibnews.com - December 20 at 11:59 AM
News IconEV in Focus on Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Liberty News (NASDAQ:LJPC)
libertynewsrecord.com - December 19 at 10:46 AM
investornewswire.com logoStrong Sell Recommendations Of La Jolla Pharmaceutical Company (NASDAQ:LJPC) At 0 - Investor Newswire (NASDAQ:LJPC)
www.investornewswire.com - December 12 at 11:29 PM
News IconWhat The Charts Are Saying About La Jolla Pharmaceutical Company (NASDAQ:LJPC) - The Business Journal (NASDAQ:LJPC)
belmontbusinessjournal.com - December 12 at 11:29 PM
News IconROIC Focus on Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Liberty News (NASDAQ:LJPC)
libertynewsrecord.com - December 12 at 11:29 PM
insidermonkey.com logoHedge Funds Are Betting On La Jolla Pharmaceutical Company (LJPC) (NASDAQ:LJPC)
www.insidermonkey.com - December 12 at 6:27 PM
stocksdaily.net logoWill La Jolla Pharmaceutical Company (NASDAQ:LJPC) Surprise ... - Stocks Daily (NASDAQ:LJPC)
www.stocksdaily.net - December 9 at 11:21 PM
News IconNow That We Have a Cure for Hepatitis C, What Are the Next Treatment Challenges? (NASDAQ:LJPC)
www.thebodypro.com - December 8 at 10:19 AM
News IconThere Will Be Swamp | Michael Krieger (NASDAQ:LJPC)
geopolitics.co - December 8 at 10:19 AM
News IconCompany Watch: Focusing on Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Liberty News (NASDAQ:LJPC)
libertynewsrecord.com - December 7 at 11:17 PM
News IconShares in View: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - OIB News (NASDAQ:LJPC)
oibnews.com - December 6 at 6:04 PM
News IconTop Stock With Upside & Growth Potential: La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Prospect Journal (NASDAQ:LJPC)
prospectjournal.com - December 6 at 10:07 AM
News IconChecking ROIC Numbers for La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Liberty News (NASDAQ:LJPC)
libertynewsrecord.com - December 6 at 10:07 AM
investornewswire.com logoCan Shares Of La Jolla Pharmaceutical Company (NASDAQ:LJPC) Hit $80? - Investor Newswire (NASDAQ:LJPC)
www.investornewswire.com - December 5 at 6:30 PM
News IconInvestor Corner: Checking the Numbers for La Jolla Pharmaceutical Company (NASDAQ:LJPC) - Liberty News (NASDAQ:LJPC)
libertynewsrecord.com - December 2 at 7:37 AM
News IconMF Rank in Focus for La Jolla Pharmaceutical Company (NASDAQ:LJPC) - OIB News (NASDAQ:LJPC)
oibnews.com - November 30 at 11:27 PM
News IconWhat are Brokerage Firms Saying About La Jolla Pharmaceutical Company (NASDAQ:LJPC)? - CSZ News (NASDAQ:LJPC)
cincysportszone.com - November 22 at 10:00 AM
News IconInvestor Watch: Checking in on Shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) - Wall Street Lion (NASDAQ:LJPC)
wslnews.com - November 22 at 10:00 AM
stocksdaily.net logoLa Jolla Pharmaceutical Company (NASDAQ:LJPC) EPS Target Set At $-1.22 - Stocks Daily (NASDAQ:LJPC)
www.stocksdaily.net - November 21 at 11:09 AM

Social

What is La Jolla Pharmaceutical Company's stock symbol?

La Jolla Pharmaceutical Company trades on the NASDAQ under the ticker symbol "LJPC."

Where is La Jolla Pharmaceutical Company's stock going? Where will La Jolla Pharmaceutical Company's stock price be in 2017?

5 analysts have issued 12-month target prices for La Jolla Pharmaceutical Company's stock. Their forecasts range from $25.00 to $75.00. On average, they anticipate La Jolla Pharmaceutical Company's share price to reach $39.40 in the next twelve months.

When will La Jolla Pharmaceutical Company announce their earnings?

La Jolla Pharmaceutical Company is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about La Jolla Pharmaceutical Company stock?

Here are some recent quotes from research analysts about La Jolla Pharmaceutical Company stock:

  • Chardan Capital analysts commented, "We believe La Jolla Pharmaceutical Company (LJPC) has thus far shown one of the more compelling and convincing rare disease strategies in biotech. By focusing on naturally-occurring peptides with well-established biological functions, LJPC has twice (with LJPC-501 and LJPC-401) been able to achieve regulatory support to move pipeline products into pivotal trials in relatively short amounts of time. With pivotal phase III (ATHOS) data for LJPC-501 (a proprietary stabilized form of angiotensin II) due perhaps imminently in 1Q17, we affirm our Buy rating in LJPC, this time focusing on product (naturally-occurring peptide; every patient responded in phase I/II) and design elements of the phase III program which give us confidence the company will produce positive ATHOS results after its prior positive published phase I/II pilot result. We also publish sensitivities to product sales, which to us imply very robust upside scenarios for investors." (1/24/2017)
  • According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (1/17/2017)

Who owns La Jolla Pharmaceutical Company stock?

La Jolla Pharmaceutical Company's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Broadfin Capital LLC (8.27%), Perceptive Advisors LLC (7.23%), Janus Capital Management LLC (6.25%), RTW Investments LP (5.95%) and Franklin Resources Inc. (5.18%). Company insiders that own La Jolla Pharmaceutical Company stock include George F Tidmarsh, Kevin C Tang and Lakhmir S Chawla.

Who sold La Jolla Pharmaceutical Company stock? Who is selling La Jolla Pharmaceutical Company stock?

La Jolla Pharmaceutical Company's stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Janus Capital Management LLC, Franklin Resources Inc., Allianz Asset Management AG and Metropolitan Life Insurance Co. NY.

Who bought La Jolla Pharmaceutical Company stock? Who is buying La Jolla Pharmaceutical Company stock?

La Jolla Pharmaceutical Company's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Broadfin Capital LLC, City Financial Investment Co Ltd and State Street Corp. Company insiders that have bought La Jolla Pharmaceutical Company stock in the last two years include George F Tidmarsh, Kevin C Tang and Lakhmir S Chawla.

How do I buy La Jolla Pharmaceutical Company stock?

Shares of La Jolla Pharmaceutical Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of La Jolla Pharmaceutical Company stock cost?

One share of La Jolla Pharmaceutical Company stock can currently be purchased for approximately $16.97.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Earnings History Chart

Earnings by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Dividend History Chart

Dividend Payments by Quarter for La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Last Updated on 2/22/2017 by MarketBeat.com Staff